Therefore, if a patient has any recent infection, or malignancy, or elderly (>65), vedolizumab is usually the preferred drug of choice for UC due to its minimal effect on the immune system and decreased risk of infections compared to TNF-alpha inhibitors.52 The gene discussed is TNF; the disease is infection.